A Phase 3 interventional study of Cold Stored Platelets and Room Temperature Platelets in Acute Blood Loss, sponsored by Philip Spinella. Completed at 27 sites in 2 countries. Open to participants aged 0 Days to 84 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Philip Spinella · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 356 studies in Hemorrhage with a site in United States — 55 open to participants now, 74 under way, 14 of them phase 3. Hemorrhage · United States.
Among the 356 studies in Hemorrhage with a site in United States, this one is the 20th largest by enrollment of the 257 interventional ones that give a count, is one of 16 that started in 2021, is one of 47 in phase 3, and was the 264th registered.
1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.
Browse Hemorrhage studies →55 of the 356 studies in Hemorrhage with a site in United States are open now. Recruiting first, the newest first:
Hemab ApS · Sites in United States
Ages 12–70
Columbia University · Sites in United States
Ages 18–80
University of California, Los Angeles · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Canada, Japan
Ages 18+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.
This study: 0 Days to 84 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
356 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 57 · Phase 3 57 · Phase 4 52
First in 1993; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,000 is above the median of 102 across 927 interventional studies indexed under Hemorrhage.
Median enrollment 68 across the 257 interventional studies, 123 across the 98 observational. Of the 249 that completed or were terminated, 125 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 356 have an industry lead sponsor. The 10 most frequent:
Philip Spinella is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Philip Spinella has 1 study filed under Hemorrhage — fewer than ten, so there is no comparison to draw.
27 of the studies in Hemorrhage with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04229758Phase 3University of Texas at AustinRestarting Anticoagulation After Traumatic Intracranial Hemorrhage | 2026-12 |
| NCT06664775Phase 3Corza Medical GmbHA Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery | 2026-12-31 |
| NCT04924322Phase 3Yale UniversityCatheter-Related Early Thromboprophylaxis With Enoxaparin Studies | 2027-04-30 |
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
Add all 27 to your calendar (.ics) → With an account.
Among the 356 studies in Hemorrhage with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets stored at 20-24 degrees Celsius
Biological: Room Temperature Platelets
Platelets stored at 1-6 degree Celsius
Biological: Cold Stored Platelets
Platelets stored at 1-6 degree Celsius
Platelets stored at 20-24 degrees Celsius
Hemostatic Efficacy
Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome.
Time frame: 24 hours after first study platelet transfusion
Chest Tube Output Through 24 Hours
Chest tube output will be assessed by volume
Time frame: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
Blood Product Administration
The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood
Time frame: 24 and 72 hours from start time of first study platelet transfusion
Transfusion Associated Adverse Events
As per CDC guidelines for transfusion associated adverse events
Time frame: within 7 days of first study platelet transfusion
Arterial Thrombotic Event
Stroke, MI, aortic thromboic even
Time frame: within 7 days of first study platelet transfusion
Venous Thrombotic Event
Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram
Time frame: within 7 days of first study platelet transfusion
All Cause Mortality
Death for any reason
Time frame: up to 28 days
Total Dose of Individual Hemostatic Adjuncts (Units/kg)
Antifibrinolytic and coagulation factor concentrates
Time frame: 24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (mcg/kg)
Antifibrinolytic and coagulation factor concentrates
Time frame: 24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (mg/kg)
Antifibrinolytic and coagulation factor concentrates
Time frame: 24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)
Antifibrinolytic and coagulation factor concentrates Epsilon-amino-caproic acid
Time frame: 24 and 72 hours from start time of first study platelet transfusion
Mechanical Ventilation
Number of participants with need for mechanical ventilation
Time frame: up to 28 days after first study platelet transfusion
Length of Stay
ICU and hospital length of stay
Time frame: up to 28 days
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)
Time frame: 6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement).
Time frame: 6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)
Time frame: 6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)
Time frame: 6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)
Time frame: 6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)
Time frame: 6 and 24 hours after first study platelet transfusion
Unplanned Sternal Closure Delay
Sternum left open after cardiac surgery
Time frame: prior to ICU admission
Re-exploration for Bleeding
Return to OR after ICU admission
Time frame: 24 hours first study platelet transfusion
Unplanned Extracorporeal Support Post Operatively
Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion
Time frame: within 48 hours of first study platelet transfusion
Morbidities After ICU Admission
Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock
Time frame: within 7 days of first study platelet transfusion
Measures of End Organ Injury- BUN and Creatinine
If BUN, creatinine are collected clinically.- worst value
Time frame: within 48 hours of first study platelet transfusion worst value
Measures of End Organ Injury- Lactate
If lactate was collected clinically. Worst value
Time frame: within 48 hours of first study platelet transfusion worst value
Measures of End Organ Injury- Troponin
If lactate was collected clinically. Worst value
Time frame: within 48 hours of first study platelet transfusion.
Measures of End Organ Injury- ALT and AST
If lactate was collected clinically. Worst value
Time frame: within 48 hours of first study platelet transfusion.
| Milestone | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Started | 340 | 660 |
| Completed | 334 | 637 |
| Not completed | 6 | 23 |
Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome.
| Perioperative Bleeding score | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Hemostatic Efficacy | 3.0 ± 1.1 | 3.1 ± 1.2 |
Chest tube output will be assessed by volume
| mL/kg | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Chest Tube Output Through 24 Hours | 12.8 ± 12 | 13.9 ± 16.4 |
The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood
| mL/kg | Room Temperature Platelets Within 24 Hours of First Platelet Transfusion | Cold Stored Platelets Within 24 Hours of the First Platelet Transfusion | Room Temperature Platelets Within 72 Hours of First Platelet Transfusion | Cold Stored Platelets Within 72 Hours of the First Platelet Transfusion |
|---|---|---|---|---|
| RBC | 4.2 ± 9.4 | 6.2 ± 16.1 | 21.5 ± 23.0 | 29.0 ± 43.3 |
| Plasma | 2.8 ± 4.6 | 4.6 ± 12.2 | 5.3 ± 11.0 | 7.6 ± 18.5 |
| Platelets | 10.8 ± 9.3 | 13.5 ± 14.3 | 11.3 ± 10.0 | 14.6 ± 16.9 |
| Cryoprecipitate | 1.7 ± 2.5 | 1.7 ± 2.5 | 1.7 ± 2.6 | 1.7 ± 2.5 |
| Whole blood | 0.1 ± 0.7 | 0.3 ± 2.7 | 0.1 ± 0.7 | 0.3 ± 2.7 |
As per CDC guidelines for transfusion associated adverse events
| Participants | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Transfusion Associated Adverse Events | 0 | 1 |
Stroke, MI, aortic thromboic even
| Participants | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Stroke | 11 | 10 |
| MI | 0 | 3 |
| Aortic Thrombotic Event | 2 | 5 |
| No Arterial Thrombotic Event | 327 | 642 |
Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram
| Participants | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Pulmonary embolism | 2 | 3 |
| Deep Vein Thrombosis | 4 | 9 |
| Catheter associated thrombotic event | 2 | 6 |
| No venous thrombotic events | 332 | 642 |
Death for any reason
| Participants | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| All Cause Mortality | 6 | 21 |
Antifibrinolytic and coagulation factor concentrates
| units/kg | Room Temperature Platelets Within 24 Hours of First Platelet Transfusion | Cold Stored Platelets Within 24 Hours of First Platelet Transfusion | Room Temperature Platelets Within 72 Hours of First Platelet Transfusion | Cold Stored Platelets Within 72 Hours of First Platelet Transfusion |
|---|---|---|---|---|
| Anit-inhibitor coagulant complex (units/kg) | 0.3 ± 1.8 | 0.2 ± 1.7 | 0.3 ± 1.8 | 0.2 ± 1.7 |
| Prothrombin complex concentrate (3 factor) (units/kg) | 0.2 ± 2.3 | 0.4 ± 3.5 | 0.2 ± 2.3 | 0.4 ± 3.5 |
| 3Prothrombin complex concentrate (factor 4) (units/kg) | 3.9 ± 18.6 | 3.8 ± 11.4 | 3.9 ± 18.6 | 3.9 ± 11.5 |
Antifibrinolytic and coagulation factor concentrates
| mcg/kg | Room Temperature Platelets Within 24 Hours of First Platelet Transfusion | Cold Stored Platelets Within 24 Hours of First Platelet Transfusion | Room Temperature Platelets Within 72 Hours of First Platelet Transfusion | Cold Stored Platelets Within 72 Hours of First Platelet Transfusion |
|---|---|---|---|---|
| DDAVP (mcg/kg) | 0.0 ± 0.1 | 0.0 ± 0.1 | 0.0 ± 0.1 | 0.0 ± 0.1 |
| Recombinant factor VIIa (rFVIIa) (mcg/kg) | 8.0 ± 32.9 | 13.2 ± 121.8 | 2.8 ± 23.9 | 13.5 ± 122.2 |
Antifibrinolytic and coagulation factor concentrates
| mg/kg | Room Temperature Platelets Within 24 Hours of First Platelet Transfusion | Cold Stored Platelets Within 24 Hours of First Platelet Transfusion | Room Temperature Platelets Within 72 Hours of First Platelet Transfusion | Cold Stored Platelets Within 72 Hours of First Platelet Transfusion |
|---|---|---|---|---|
| Antithrobim III (mg/kg) | 0.0 ± 0.9 | 0.0 ± 0.0 | 0.0 ± 0.9 | 0.0 ± 0.0 |
| Factor XIII concentrate (mg/kg) | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Factor concentrate other (mg/kg) | 0.1 ± 2.7 | 0.0 ± 0.0 | 0.1 ± 2.7 | 0.0 ± 0.0 |
| Tranexamic acid (mg/kg) | 1.7 ± 10.1 | 1.6 ± 8.9 | 1.7 ± 10.1 | 1.6 ± 8.9 |
Antifibrinolytic and coagulation factor concentrates Epsilon-amino-caproic acid
| grams/kg | Room Temperature Platelets Within 24 Hours of First Platelet Transfusion | Cold Stored Platelets Within 24 Hours of First Platelet Transfusion | Room Temperature Platelets Within 72 Hours of First Platelet Transfusion | Cold Stored Platelets Within 72 Hours of First Platelet Transfusion |
|---|---|---|---|---|
| Total Dose of Individual Hemostatic Adjuncts (Grams/kg) | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
Number of participants with need for mechanical ventilation
| Participants | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Mechanical Ventilation | 283 | 552 |
ICU and hospital length of stay
| days | Room Temperature Platelets | Cold Stored Platelets | Mixed |
|---|---|---|---|
| Length of Stay | 5.8 ± 5.8 | 5.0 ± 4.8 | 10.4 ± 8.7 |
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)
| unitless ratio | Room Temperature Platelets 6 Hours Post Transfusion | Cold Stored Platelets 6 Hours Post Transfusion | Room Temperature Platelets 24 Hours Post Transfusion | Cold Stored Platelets 24 Hours Post Transfusion |
|---|---|---|---|---|
| Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin | 0.61 ± 1.97 | 0.67 ± 1.97 | -0.13 ± 1.83 | -0.02 ± 1.91 |
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement).
| unitless ratio | Room Temperature Platelets 6 Hours Post Transfusion | Cold Stored Platelets 6 Hours Post Transfusion | Room Temperature Platelets 24 Hours Post Transufusion | Cold Stored Platelets 24 Hours Post Transfusion |
|---|---|---|---|---|
| Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit | 0.07 ± 0.19 | 0.09 ± 0.20 | 0.00 ± 0.17 | 0.02 ± 0.17 |
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)
| unitless ratio | Room Temperature Platelets 6 Hours Post Transfusion | Cold Stored Platelets 6 Hours Post Transfusion | Room Temperature Platelets 24 Hours Post Transfusion | Cold Store Platelets 24 Hours Post Transfusion |
|---|---|---|---|---|
| Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count | 0.91 ± 1.12 | 0.17 ± 0.44 | 0.60 ± 0.97 | 0.08 ± 0.47 |
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)
| unitless | Room Temperature Platelets 6 Hours Post Transfusion | Cold Stored Platelets 6 Hours Post Transfusion | Room Temperature Platelets 24 Hours Post Transfusion | Cold Store Platelets 24 Hours Post Transfusion |
|---|---|---|---|---|
| Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR | -0.25 ± 0.16 | -0.24 ± 0.15 | -0.18 ± 0.17 | -0.18 ± 0.19 |
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)
| unitless ratio | Room Temperature Platelets 6 Hours Post Transfusion | Cold Stored Platelets 6 Hours Post Transfusion | Room Temperature Platelets 24 Hours Post Transfusion | Cold Store Platelets 24 Hours Post Transfusion |
|---|---|---|---|---|
| Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT | -0.17 ± 0.41 | -0.12 ± 0.44 | -0.20 ± 0.46 | -0.16 ± 0.53 |
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)
| unitless ratio | Room Temperature Platelets 6 Hours Post Transfusion | Cold Stored Platelets 6 Hours Post Transfusion | Room Temperature Platelets 24 Hours Post Transfusion | Cold Store Platelets 24 Hours Post Transfusion |
|---|---|---|---|---|
| Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen | 0.46 ± 0.43 | 0.44 ± 0.47 | 1.01 ± 0.66 | 1.04 ± 0.66 |
Sternum left open after cardiac surgery
| Participants | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Unplanned Sternal Closure Delay | 5 | 20 |
Return to OR after ICU admission
| Participants | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Re-exploration for Bleeding | 6 | 28 |
Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion
| Participants | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Unplanned Extracorporeal Support Post Operatively | 11 | 25 |
Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock
| Participants | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Acute respiratory distress syndrome | 8 | 20 |
| Need for renal support | 17 | 27 |
| Renal failure | 23 | 41 |
| Septic Shock | 3 | 7 |
| No morbidities | 289 | 565 |
If BUN, creatinine are collected clinically.- worst value
| mg/dL | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| BUN | 20.0 (16.0 to 28.0) | 20 (15.0 to 25.1) |
| Creatinine | 1.1 (0.7 to 1.4) | 1.1 (0.7 to 1.4) |
If lactate was collected clinically. Worst value
| mmol/L | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Measures of End Organ Injury- Lactate | 3.5 (2.0 to 6.3) | 3.7 (2.3 to 7.2) |
If lactate was collected clinically. Worst value
| mg/mL | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| Measures of End Organ Injury- Troponin | 6.3 (4.7 to 22.1) | 6.3 (3.0 to 13.4) |
If lactate was collected clinically. Worst value
| U/L | Room Temperature Platelets | Cold Stored Platelets |
|---|---|---|
| ALT | 24.0 (16.0 to 37.0) | 22.0 (16.0 to 34.0) |
| AST | 74.54 (41.5 to 112.5) | 75.0 (46.0 to 119.0) |
Collected over Adverse events were collected up to 28 days after platelet transfusion. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Room Temperature Platelets | 6/342 (1.8%) | 147/342 (43%) | 204/342 (59.6%) |
| Cold Stored Platelets | 9/566 (1.6%) | 99/566 (17.5%) | 347/566 (61.3%) |
| Mixed | 12/92 (13%) | 77/92 (83.7%) | 77/92 (83.7%) |
| Event | Room Temperature Platelets | Cold Stored Platelets | Mixed |
|---|---|---|---|
| cardiac disordersCardiac disorders | 37/342 | 66/566 | 21/92 |
| respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 25/342 | 41/566 | 15/92 |
| Infections and infestationsInfections and infestations | 10/342 | 18/566 | 9/92 |
| Surgical and medical proceduresSurgical and medical procedures | 4/342 | 6/566 | 9/92 |
| Vascular disordersVascular disorders | 14/342 | 8/566 | 9/92 |
| injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 6/342 | 9/566 | 8/92 |
| Renal and urinary disordersRenal and urinary disorders | 15/342 | 12/566 | 6/92 |
| nervous system disordersNervous system disorders | 13/342 | 14/566 | 5/92 |
| General disorders and administration site conditionsGeneral disorders | 4/342 | 10/566 | 4/92 |
| Gastrointestinal disordersGastrointestinal disorders | 9/342 | 9/566 | 0/92 |
| Event | Room Temperature Platelets | Cold Stored Platelets | Mixed |
|---|---|---|---|
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 74/342 | 146/566 | 31/92 |
| Vascular disordersVascular disorders | 71/342 | 93/566 | 31/92 |
| Cardiac disordersCardiac disorders | 55/342 | 92/566 | 27/92 |
| General disorders and administarion site conditionsGeneral disorders | 48/342 | 79/566 | 19/92 |
| Renal and urinary disordersRenal and urinary disorders | 38/342 | 47/566 | 16/92 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 12/342 | 21/566 | 12/92 |
| Surgical and medical proceduresSurgical and medical procedures | 7/342 | 12/566 | 12/92 |
| Metabolic and nutrition disordersMetabolism and nutrition disorders | 43/342 | 73/566 | 7/92 |
| Infections and infestationsInfections and infestations | 17/342 | 28/566 | 11/92 |
| Blood and lymphatic system disordersBlood and lymphatic system disorders | 20/342 | 42/566 | 7/92 |
| Age, Continuous(Years) | Room Temperature Platelets | Cold Stored Platelets | Total |
|---|---|---|---|
| Mean | 41.8 ± 30.4 | 42.3 ± 30 | 42.1 ± 55.4 |
| Sex: Female, Male(Participants) | Room Temperature Platelets | Cold Stored Platelets | Total |
|---|---|---|---|
| Female | 118 | 204 | 322 |
| Male | 222 | 456 | 678 |
| Ethnicity (NIH/OMB)(Participants) | Room Temperature Platelets | Cold Stored Platelets | Total |
|---|---|---|---|
| Hispanic or Latino | 38 | 81 | 119 |
| Not Hispanic or Latino | 287 | 555 | 842 |
| Unknown or Not Reported | 15 | 24 | 39 |
| Region of Enrollment(participants) | Room Temperature Platelets | Cold Stored Platelets | Total |
|---|---|---|---|
| United States | 310 | 616 | 926 |
| Australia | 30 | 44 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Mar 2025, 41 months.
Results were first posted in Nov 2026, 1 year 7 months after primary completion.
Of 45 non-industry phase 3 interventional studies under Hemorrhage, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 41 months is close to that.
Counting every sponsor, half of 72 studies reached it within 42 months; a quarter within 26 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Philip Spinella